NCT05254613View on ClinicalTrials.gov

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions
Healthy
Interventions
DRUG

ALXN1830

ALXN1830 will be administered as SC infusion(s).

DRUG

Placebo

Placebo will be administered as SC infusion(s).

Trial Locations (1)

Unknown

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY